- Home
- ATAI vs ANGO Comparison
ATAI vs ANGO Comparison
Compare ATAI & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | ANGO |
|---|---|---|
| Founded | 2018 | 1988 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 550.8M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ATAI | ANGO |
|---|---|---|
| Price | $4.10 | $13.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $14.33 | ★ $19.33 |
| AVG Volume (30 Days) | ★ 3.2M | 417.7K |
| Earning Date | 11-12-2025 | 01-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,018,000.00 | ★ $300,718,000.00 |
| Revenue This Year | $943.18 | $8.18 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | 2.73 |
| 52 Week Low | $1.15 | $8.27 |
| 52 Week High | $6.75 | $13.99 |
Technical Indicators
Market Signals| Indicator | ATAI | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 52.98 |
| Support Level | $3.88 | $13.12 |
| Resistance Level | $4.72 | $13.91 |
| Average True Range (ATR) | 0.25 | 0.37 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 23.81 | 24.27 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.